PHARMACOLOGY-GUIDED RULE-BASED ADAPTIVE DOSE ESCALATION IN FIRST-IN-HUMAN STUDIES.

被引：0
|
作者：
van Hoogdalem, E. [1 ]
Van Lersel, T. [1 ]
Winter, E. [2 ]
Constant, J. [3 ]
机构：
[1] PRA Hlth Sci, Groningen, Netherlands
[2] PRA Hlth Sci, Blue, PA USA
[3] PRA Hlth Sci, Victoria, BC, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OII-001
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [21] Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis
    Jung, David
    Braun, Inka Valeska
    Wensing, Georg
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (01) : 1 - 7
  • [22] A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials
    Jiang, Zehui
    Sun, Wenxuan
    Du, Rui
    Yang, Rui
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09): : 2388 - 2392
  • [23] Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasma
    Cancelas, Jose A.
    Nestheide, Shawnagay
    Rugg, Neeta
    Eckerman, Anna
    Macdonald, Victor W.
    L. Charles, Matthew
    Markstrom, Luke
    Atkinson, Andrew J.
    King, Melissa R.
    Snyder, Michele
    Burgess, David
    Murto, James
    Valiyaveettil, Manoj K.
    C. Pehta, Joan
    Penegor, Stephen A.
    TRANSFUSION, 2022, 62 (02) : 406 - 417
  • [24] Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies
    Goldstein, Matthew J.
    Peters, Malte
    Weber, Barbara L.
    Davis, Charles B.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (02): : 536 - 543
  • [25] SAFETY AND IMMUNOGENICITY OF A REPLICATION DEFICIENT SIMIAN ADENOVIRAL VECTORED CHIKUNGUNYA VACCINE: A PHASE I, FIRST-IN-HUMAN, DOSE ESCALATION TRIAL
    Folegatti, Pedro M.
    Harrison, Kate
    Lopez, Fernando Ramos
    Tilley, Mark W.
    Lopez-Camacho, Cesar
    Kim, Young C.
    Preciado-Llanes, Lorena
    Rossi, Shannan L.
    Poulton, Ian
    Jenkin, Daniel
    Datoo, Mehreen
    Themistocleous, Yrene
    Lawrie, Alison
    Roberts, Rachel
    Ewer, Katie
    Berrie, Eleanor
    Hill, Adrian
    Reyes-Sandoval, Arturo
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2019, 101 : 19 - 19
  • [26] First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.
    Segal, Neil Howard
    Naidoo, Jarushka
    Curigliano, Giuseppe
    Patel, Sandip
    Sahebjam, Solmaz
    Papadopoulos, Kyriakos P.
    Gordon, Michael S.
    Wang, Ding
    Rueda, Ana Gomez
    Song, Xuyang
    Li, Xia
    Marshall, Shannon
    Abdullah, Shaad Essa
    Diamond, Jennifer Robinson
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors.
    Infante, Jeffrey R.
    Naing, Aung
    Papadopoulos, Kyriakos P.
    Autio, Karen A.
    Ott, Patrick Alexander
    Wong, Deborah Jean Lee
    Falchook, Gerald Steven
    Patel, Manish R.
    Pant, Shubham
    Whiteside, Melinda
    Bendell, Johanna C.
    Bauer, Todd Michael
    Janku, Filip
    Javle, Milind M.
    Hong, David S.
    Oft, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] ATRiUM: A first-in-human dose escalation phase I trial of ceralasertib (AZD6738) and gemcitabine as combination therapy.
    de Paula, Bruno Henrique
    Basu, Bristi
    Mander, Adrian
    Khan, Josephine
    Bundi, Purity
    Goodwin, Richard
    Thaventhiran, James
    Alberto, Gonzalez-Lopes
    Edmund, Godfrey
    Islam, Sabita
    Anand, Subha
    Evans, Jeff
    Graziano, Vincenzo
    Serrao, Eva
    Pawula, Maria
    Hernandez, Tatiana
    Dean, Emma
    Smith, Simon
    Jodrell, Duncan
    CANCER RESEARCH, 2021, 81 (13)
  • [29] First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort
    Yu, Jinming
    Sun, Yuping
    Dang, Qi
    Zhang, Yan
    Du, Jintong
    Wei, Yonggang
    Ye, Fei
    Liu, Rui
    Zhao, Qi
    Li, Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies
    Sato, Akihide
    Narukawa, Mamoru
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (09) : 770 - 775
12345